Background: Venous malformations (VMs) are the most common type of vascular malformations; maxillofacial VMs result in functional and esthetic problems. Sclerotherapy is their main treatment. Aim of Study: to compare between Bleomycin (BLM) and Ethanolamine Oleate (EO) sclerosing agents in treatment of maxillofacial VMs to decide which can achieve better therapeutic results, with fewer complications. Materials and Methods: 30 children having maxillofacial VMs were divided into two equal groups. BLM was injected at 4 weeks interval, and EO was injected at 2 weeks interval. Clinical response was classified into: complete resolution, marked improvement, moderate improvement, or no improvement. Results were compared after 12 months. Results: BLM Group: complete resolution in 12\15 patients, marked improvement in 3\15 patients. Treatment duration ranged from 2 to 8 months. EO Group: complete resolution in 7\15 patients, marked improvement in 4\15 patients, moderate improvement in 3\15 patients, and no response in one patient. Treatment duration ranged from 1 to 3 months. Difference between 2 groups was non-significant in clinical response and recurrence. BLM required significantly less local anaesthesia and had significantly less pain, but required significantly longer treatment duration than EO. Conclusion: BLM has fewer complications than EO; however, BLM requires longer treatment duration. EO is effective and safe only for intra-oral VMs and should be performed under GA to avoid local anesthesia systemic toxicity.